ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER).
ISOLYTE M in Dextrose 5% is a crystalloid solution that provides water, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. The electrolytes (sodium, potassium, magnesium, chloride, acetate, and gluconate) maintain or restore intravascular volume and acid-base balance. Acetate and gluconate are bicarbonate precursors, metabolized in the liver and peripheral tissues to generate bicarbonate, thus correcting metabolic acidosis.
| Metabolism | Dextrose undergoes glycolysis and the Krebs cycle to produce ATP, carbon dioxide, and water. Acetate is metabolized in the liver and peripheral tissues to form acetyl-CoA, which enters the Krebs cycle, generating bicarbonate. Gluconate is metabolized via the pentose phosphate pathway to produce ribulose-5-phosphate and eventually bicarbonate. |
| Excretion | Primarily renal; >90% of infused water and electrolytes are excreted unchanged via kidneys with minimal biliary or fecal elimination. |
| Half-life | No true terminal half-life; infused components (water and electrolytes) follow endogenous kinetics. Dextrose half-life approx. 1-2 hours, electrolytes distribute and are excreted based on renal function. |
| Protein binding | Negligible for water and electrolytes; dextrose not bound. Total protein binding <5%. |
| Volume of Distribution | Sodium distributes primarily in extracellular fluid (Vd ~0.2 L/kg); water distributes in total body water (Vd ~0.6 L/kg). Dextrose distributes in extracellular and intracellular fluid with Vd ~0.2 L/kg initial. |
| Bioavailability | Intravenous: 100% bioavailability for all components; not administered by other routes. |
| Onset of Action | Intravenous: immediate (seconds to minutes) for hemodynamic effects; electrolyte correction begins within minutes of infusion. |
| Duration of Action | Duration of electrolyte repletion correlates with infusion rate (1-2 hours per liter typically); volume effect lasts for duration of infusion plus renal excretion (2-4 hours after stop). Clinical duration depends on ongoing losses. |
| Molecular Weight | Dextrose: 180.16 Da; Electrolytes (nominal): Na+ 22.99, K+ 39.10, Mg2+ 24.31, Cl- 35.45, acetate 59.04 |
Intravenous infusion; dose determined by fluid and electrolyte requirements; typical adult rate 100-200 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | Use with caution; monitor serum potassium and adjust infusion rate based on renal function; no specific GFR-based dose reduction defined. |
| Liver impairment | No specific adjustment required; monitor electrolytes in severe hepatic impairment. |
| Pediatric use | Intravenous infusion; dose individualized based on weight and clinical status; typical rate 5-10 mL/kg/hour. |
| Geriatric use | Use with caution due to possible renal impairment; monitor fluid and electrolyte status; adjust rate to avoid volume overload. |
| 1st trimester | Generally considered safe when used as directed. Dextrose and electrolytes are essential for maternal and fetal hydration and nutrition. No known teratogenic effects. |
| 2nd trimester | Safe for use as directed. Monitor for electrolyte imbalances and fluid overload, especially in conditions like preeclampsia. |
| 3rd trimester | Safe for use as directed. Use caution in late pregnancy due to risk of fluid overload and maternal hyperglycemia, which may cause fetal hyperinsulinemia and neonatal hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Dextrose and electrolytes cross the placenta. Dextrose transfer is carrier-mediated and equilibrates rapidly. Electrolytes (sodium, potassium, magnesium, chloride, acetate) cross via active transport and diffusion. |
| Breastfeeding | Compatible with breastfeeding. Dextrose and electrolytes pass into breast milk in amounts that are not expected to harm the nursing infant. Monitor maternal blood glucose if high doses are infused. |
| Lactation Rating | L1 - Compatible |
| Teratogenic Risk | Isolyte M in Dextrose 5% is an intravenous electrolyte and caloric solution. At therapeutic doses, no teratogenic risk has been identified in animal studies; however, human data are limited. Inadvertent administration of large volumes leading to hyperglycemia or electrolyte imbalances (e.g., hyponatremia) could pose risks to the fetus. Use only when clearly needed and monitor maternal glucose and electrolytes closely. |
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, potassium, magnesium, calcium, chloride), glucose, acid-base status, renal function, and fluid balance. Fetal monitoring (ultrasound, fetal heart rate) is indicated if maternal metabolic disturbances occur. Assess for signs of fluid overload (e.g., hypertension, edema) or electrolyte imbalance. |
| Fertility Effects | No known adverse effects on fertility from dextrose or electrolytes at therapeutic doses. However, underlying conditions requiring this solution may impact fertility. No specific human studies available. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentHyperglycemia with severe dehydrationSevere electrolyte disorders (e.g., hyperkalemia, hypermagnesemia)Severe metabolic acidosisPulmonary edema or severe cardiac decompensationAcute myocardial infarction with pulmonary edema
| Precautions | Use with caution in patients with renal impairment, heart failure, or conditions causing fluid overload., Monitor serum electrolytes, blood glucose, and fluid balance., Risk of hyperglycemia, hyperosmolarity, and dilutional hyponatremia., Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis., Avoid rapid infusion to prevent metabolic acidosis from lactate accumulation (acetate may cause alkalosis if excessive). |
| Food/Dietary | No specific food interactions. However, patients should maintain a balanced diet as per their medical condition. Avoid excessive intake of potassium-rich foods if at risk of hyperkalemia. |
| Clinical Pearls | Check serum potassium, magnesium, and phosphate levels before infusion; monitor serum glucose closely due to dextrose content. Adjust infusion rate based on volume status and renal function. Use with caution in patients with renal impairment or hyperkalemia. Ensure compatibility with co-administered IV medications. |
| Patient Advice | This solution provides fluids, electrolytes, and calories to maintain hydration and electrolyte balance. · Report any signs of fluid overload (e.g., shortness of breath, swelling) or allergic reactions (e.g., rash, itching). · Inform your healthcare provider if you have kidney problems, diabetes, or are on a salt-restricted diet. · The infusion may cause changes in blood sugar levels; monitoring may be required if you have diabetes. |
Loading safety data…